Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC67759 Lapatinib-d4 Lapatinib-d4 Chemical Structure
  3. GC16021 Lavendustin A EGFR tyrosine kinase inhibitor Lavendustin A Chemical Structure
  4. GC19218 Lazertinib Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib Chemical Structure
  5. GC13117 Lck Inhibitor A selective inhibitor of lymphocyte-specific protein tyrosine kinase Lck Inhibitor Chemical Structure
  6. GC36430 Lck inhibitor 2 Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively Lck inhibitor 2 Chemical Structure
  7. GC14241 LDC1267 TAM kinase inhibitor,highly selective LDC1267 Chemical Structure
  8. GC14552 LDK378 LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. LDK378 Chemical Structure
  9. GC17452 LDK378 dihydrochloride LDK378 dihydrochloride Chemical Structure
  10. GC50327 LDN 193189 dihydrochloride Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs LDN 193189 dihydrochloride Chemical Structure
  11. GC33086 LDN-192960 LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively. LDN-192960 Chemical Structure
  12. GC44047 LDN-192960 (hydrochloride) LDN-192960 is an inhibitor of haspin protein kinase and dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) with IC50 values of 10 and 48 nM, respectively. LDN-192960 (hydrochloride) Chemical Structure
  13. GC38403 LDN-192960 hydrochloride LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively. LDN-192960 hydrochloride Chemical Structure
  14. GC16580 LDN-193189 ALK inhibitor,potent and selective LDN-193189 Chemical Structure
  15. GC16798 LDN-211904 LDN-211904 (compound 32) is a potent and selective EphB3 inhibitor with an IC50 of 0.079 μM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC. LDN-211904 Chemical Structure
  16. GC17035 LDN-212854 BMP receptor inhibitor,potent and selective LDN-212854 Chemical Structure
  17. GC13225 LDN-214117 potent and selective ALK2 inhibitor LDN-214117 Chemical Structure
  18. GC14931 LDN193189 Hydrochloride An inhibitor of BMP receptors ALK1, ALK2, ALK3, and ALK6 LDN193189 Hydrochloride Chemical Structure
  19. GC15454 Lenvatinib (E7080) Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. Lenvatinib (E7080) Chemical Structure
  20. GC36438 Lenvatinib mesylate An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate Chemical Structure
  21. GC17033 Lestaurtinib A potent JAK2 and PRK1 kinase inhibitor Lestaurtinib Chemical Structure
  22. GC17958 Linifanib (ABT-869) Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869) Chemical Structure
  23. GC15749 Linsitinib IGF1R/IR inhibitor,potent and novel Linsitinib Chemical Structure
  24. GC47570 Lipoxygenin An inhibitor of 5-LO Lipoxygenin Chemical Structure
  25. GC17835 LM 22A4 tropomyosin-related kinase B (TrkB) agonist LM 22A4 Chemical Structure
  26. GC30770 LM22B-10 An activator of TrkB and TrkC LM22B-10 Chemical Structure
  27. GC36425 LOXO-101 (Larotrectinib) LOXO-101 (Larotrectinib) (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). LOXO-101 (Larotrectinib) Chemical Structure
  28. GC15282 LOXO-101 (Larotrectinib) sulfate LOXO-101 (Larotrectinib) sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). LOXO-101 (Larotrectinib) sulfate Chemical Structure
  29. GC19547 LOXO-292 LOXO-292 (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. LOXO-292 has anticancer activity. LOXO-292 Chemical Structure
  30. GC65390 LRRK2 inhibitor 1 LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC50 of 6.8. LRRK2 inhibitor 1 Chemical Structure
  31. GC10809 LRRK2-IN-1 A selective LRRK2 inhibitor LRRK2-IN-1 Chemical Structure
  32. GC69410 Lumretuzumab

    Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized monoclonal antibody that targets HER3 (ERBB3) and can be used for cancer research.

     Lumretuzumab Chemical Structure
  33. GC13848 LY2784544 Potent inhibitor of JAK2 LY2784544 Chemical Structure
  34. GC11057 LY2801653 A MET kinase inhibitor LY2801653 Chemical Structure
  35. GC13424 LY2874455 A pan-FGFR inhibitor LY2874455 Chemical Structure
  36. GC40865 LYG-202 LYG-202 is a synthetic flavonoid with anticancer and anti-angiogenic activities. LYG-202 Chemical Structure
  37. GC62314 M4205 M4205 is a c-KIT inhibitor, with an IC50 of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17. M4205 Chemical Structure
  38. GC68304 Margetuximab Margetuximab Chemical Structure
  39. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate Chemical Structure
  40. GC66349 Mavrilimumab Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. Mavrilimumab Chemical Structure
  41. GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 Chemical Structure
  42. GC64583 MAX-40279 hemiadipate MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate Chemical Structure
  43. GC64582 MAX-40279 hemifumarate MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate Chemical Structure
  44. GC16483 MAZ51 VEGFR3 antagonist MAZ51 Chemical Structure
  45. GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate. MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Chemical Structure
  46. GC14951 Meleagrin antibiotic Meleagrin Chemical Structure
  47. GC36585 Merestinib dihydrochloride Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM). Merestinib dihydrochloride Chemical Structure
  48. GC68018 MET kinase-IN-2 MET kinase-IN-2 Chemical Structure
  49. GC12069 Methyl 2,5-dihydroxycinnamate EGF receptor-associated tyrosine kinases inhibitor Methyl 2,5-dihydroxycinnamate Chemical Structure
  50. GC36596 Methylnissolin Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. Methylnissolin Chemical Structure
  51. GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity. MGCD-265 Chemical Structure
  52. GC61516 MID-1 MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 Chemical Structure
  53. GC32819 Mirk-IN-1 (Dyrk1B/A-IN-1) Mirk-IN-1 (Dyrk1B/A-IN-1) is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively. Mirk-IN-1 (Dyrk1B/A-IN-1) Chemical Structure
  54. GC16337 MK-2461 C-Met (WT/mutants) inhibitor MK-2461 Chemical Structure
  55. GC13140 MK-8033 MK-8033 Chemical Structure
  56. GC36625 MK-8033 hydrochloride MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs). MK-8033 hydrochloride Chemical Structure
  57. GC47687 ML-209 An RORγt antagonist ML-209 Chemical Structure
  58. GC17582 ML347 BMP receptor inhibitor,potent and selective ML347 Chemical Structure
  59. GC30769 MLi-2 An LRRK2 inhibitor MLi-2 Chemical Structure
  60. GC10775 MLR 1023 MLR 1023 is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM. MLR 1023 Chemical Structure
  61. GC10048 MNS Inhibitor of Src/Syk tyrosine kinases MNS Chemical Structure
  62. GC47697 Mobocertinib An inhibitor of mutant EGFR and HER2 receptors Mobocertinib Chemical Structure
  63. GC62160 Mobocertinib succinate Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research. Mobocertinib succinate Chemical Structure
  64. GC13012 Motesanib Motesanib Chemical Structure
  65. GC11336 Motesanib Diphosphate (AMG-706) Motesanib Diphosphate (AMG-706) (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret. Motesanib Diphosphate (AMG-706) Chemical Structure
  66. GC69496 MRL-871

    MRL-871 (compound 3) is an effective inverse agonist of retinoic acid receptor-related orphan receptor gamma t (RORγt), with an IC50 of 264 nM. MRL-871 has a unique imidazole chemical structure and can effectively reduce the generation of IL-17a mRNA in EL4 cells.

     MRL-871 Chemical Structure
  67. GC13525 MRS 4062 triethylammonium salt P2Y4 receptor agonist MRS 4062 triethylammonium salt Chemical Structure
  68. GC32769 MRX-2843 (UNC2371) MRX-2843 (UNC2371) (UNC2371) is an orally active, ATP-competitive dual MERTK and FLT3 tyrosine kinases inhibitor (TKI) with enzymatic IC50s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively. MRX-2843 (UNC2371) Chemical Structure
  69. GC65243 MS4077 MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37?nM for binding affinity to ALK. MS4077 Chemical Structure
  70. GC64966 MS4078 MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK. MS4078 Chemical Structure
  71. GC15936 MSDC-0160 mTOT-modulating insulin sensitizer MSDC-0160 Chemical Structure
  72. GC64431 MSDC-0602K MSDC-0602K (Azemiglitazone potassium), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. MSDC-0602K Chemical Structure
  73. GC19256 MTX-211 MTX-211 is a dual inhibitor of EGFR and PI3K, used for the treatment of cancer and other diseases. MTX-211 Chemical Structure
  74. GC10250 Mubritinib (TAK 165) Mubritinib (TAK 165) (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM. Mubritinib (TAK 165) Chemical Structure
  75. GC11126 Mutant EGFR inhibitor Selective Mutated EGFR inhibitor Mutant EGFR inhibitor Chemical Structure
  76. GC36666 Mutated EGFR-IN-1 Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant. Mutated EGFR-IN-1 Chemical Structure
  77. GC36667 Mutated EGFR-IN-2 Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=＜1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity. Mutated EGFR-IN-2 Chemical Structure
  78. GC44263 Myrtillin Myrtillin (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in bilberry extract. Myrtillin induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL). Myrtillin exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM. Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 μM. Myrtillin Chemical Structure
  79. GC40567 N-(p-Coumaroyl) Serotonin N-(p-Coumaroyl) serotonin is an antioxidative phenolic naturally found in plants, including safflower seed and millet grain. N-(p-Coumaroyl) Serotonin Chemical Structure
  80. GC11526 N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide Phosphopeptide for binding to the src SH2 domain N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide Chemical Structure
  81. GC12746 N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Phosphopeptide ligand for the src SH2 domain N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Chemical Structure
  82. GC15365 N-Acetylserotonin N-Acetylserotonin is a Melatonin precursor, and that it can potently activate TrkB receptor. N-Acetylserotonin Chemical Structure
  83. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide Chemical Structure
  84. GC44290 NAADP (sodium salt)

    Nicotinic acid adenine dinucleotide phosphate (NAADP) is a secondary messenger that induces calcium mobilization.

     NAADP (sodium salt) Chemical Structure
  85. GC33045 NAMI-A NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration. NAMI-A Chemical Structure
  86. GC33022 Naquotinib (ASP8273) Naquotinib (ASP8273) (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. Naquotinib (ASP8273) Chemical Structure
  87. GC32836 Naquotinib mesylate (ASP8273) Naquotinib mesylate (ASP8273) (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. Naquotinib mesylate (ASP8273) Chemical Structure
  88. GC36699 Nazartinib mesylate Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively. Nazartinib mesylate Chemical Structure
  89. GC40623 NBI 31772 NBI 31772 is a nonpeptide ligand that releases insulin-like growth factor-1 (IGF-1) from its binding protein (IGFBP; Kis = 1-24 nM for the six human subtypes of IGFBP). NBI 31772 Chemical Structure
  90. GC61111 NBI-31772 hydrate NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate Chemical Structure
  91. GC10644 Neoruscogenin nuclear receptor RORα agonist Neoruscogenin Chemical Structure
  92. GC10362 Neratinib (HKI-272) Neratinib (HKI-272) (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively. Neratinib (HKI-272) Chemical Structure
  93. GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1 NG 25 (hydrochloride hydrate) Chemical Structure
  94. GC60270 Nilotinib D6 An internal standard for the quantification of nilotinib Nilotinib D6 Chemical Structure
  95. GC25669 Nilotinib hydrochloride Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Nilotinib hydrochloride Chemical Structure
  96. GC14237 Nilotinib monohydrochloride monohydrate A Bcr-Abl inhibitor Nilotinib monohydrochloride monohydrate Chemical Structure
  97. GC14129 Nilotinib(AMN-107) A Bcr-Abl inhibitor Nilotinib(AMN-107) Chemical Structure
  98. GC62601 Nimotuzumab Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor drug, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab Chemical Structure
  99. GC18211 Ningetinib A multi-kinase inhibitor Ningetinib Chemical Structure
  100. GC36744 Ningetinib Tosylate Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib Tosylate Chemical Structure
  101. GC11705 Nintedanib (BIBF 1120) A VEGFR, FGFR, and PDGFR inhibitor Nintedanib (BIBF 1120) Chemical Structure

Items 601 to 700 of 1115 total

per page
  2. 5
  3. 6
  4. 7
  5. 8
  6. 9

Set Descending Direction